Sign In

BioMaryland Center Awards $865,000 to Accelerate Life Sciences Commercialization

​BALTIMORE, MD (February 25, 2015) – The BioMaryland Center announced today that it has awarded $865,000 to five growing life sciences companies and one medical institution through its Biotechnology Development Awards program. The companies, which received up to $200,000 each, will use the funding to accelerate the commercialization of a wide range of treatments and technologies; including a device that monitors congestive heart failure; a portable PET scanner; and a device to detect arterial graft failure that would have resulted in avoidable amputations. An award was also given to a Johns Hopkins School of Medicine surgeon for his work with a novel treatment of brain cancer. The BioMaryland Center is part of the Maryland Department of Business and Economic Development (DBED).

"These awards provide critical funding and help to ensure that the life-saving research being done at these companies has the opportunity to move to the commercial marketplace and potentially impact million around the world," said DBED Secretary Mike Gill. 

For this year's awards, the BioMaryland Center launched a new partnership with Maryland's Department of Health and Mental Hygiene (DHMH) and the Center for Medical Technology Policy (CMTP) to incorporate improved health care quality and cost reduction criteria into the selection process. The awards were made on a competitive basis, with preference given to projects that improve patient outcomes and reduce health care costs. The BioMaryland Center, DHMH and CMTP will provide ongoing advice and support to the companies selected for funding and help address any technical, scientific, regulatory and reimbursement issues that may be encountered during the development process.

Since its inception in 2010, more than $8.3 million has been awarded through the program to advance 48 Maryland life sciences projects. Three previous awardees – Gliknik, Telcare, and Unither Virology – collectively have raised more than $130 million after using their biotechnology development award funds to advance the early stages of their technology.

Awardees this round are:
  • Brain Biosciences (Rockville) – A compact portable PET scanner for evaluation of patients with suspected Alzheimer’s or other neurodegenerative disorders.  
  • GraftWorx LLC (Bel Air) – A “smart” graft that automatically alerts clinicians of critical events before they occur so that cost-effective, early interventions replace emergency procedures.
  • JPLC Associates (Baltimore) – A device, the “Raven,” which integrates optical, mechanical and radiation quality assurance parameters for radiation therapy equipment.
  • Mindoula Health (Silver Spring) – A telehealth platform enabling virtual and in-person 24/7 behavioral health case management services and collaborative care.
  • Vixiar Medical Inc. (Annapolis) – A noninvasive device to monitor congestive heart failure that functions by having the patient breathe into a hand-held device to use airway back pressure to calculate cardiac filling pressures.
  • Dr. Quinones-Hinojosa and Dr. Jordan Green, Johns Hopkins School of Medicine (Baltimore) - A biodegradable nanoparticle therapy enabling effective transfection of patient’s stem cells derived from adipose tissue that are applied directly to the post-operative site of brain cancer.   

ABOUT BIOMARYLAND CENTER
The BioMaryland Center is the office within Maryland's Department of Business and Economic Development which connects life sciences companies, academic and federal researchers with each other and with potential capital sources, partners, clients, and other resources. Center staff provides information regarding funding and other resources, business plan feedback, and access to market research, advocacy, ​and other industry support. The BioMaryland Center also promotes the state's life sciences industry domestically and abroad. For more information regarding the Center and the Biotechnology Development awards program, visit www.Bio.Maryland.gov.

ABOUT DBED
The Maryland Department of Business and Economic Development stimulates private investment and creates jobs by attracting new businesses, encouraging the expansion and retention of existing companies, and providing workforce training and financial assistance to Maryland companies. The Department promotes the State's many economic advantages and markets local products and services at home and abroad to spur economic development and international investment, trade and tourism. For more information, visit www.ChooseMaryland.org​.

​​

Close window
Close Disclaimer

Google Translate Disclaimer

The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology ​​​to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.